News | April 27, 2024
AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Breakthrough Therapy designation for pain associated with DPN granted by FDA
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Subscribe To Our Newsletter & Stay Updated
